Search
Displaying all 2 results
Ustekinumab
go.drugbank.com/drugs/DB05679
ApprovedInvestigational
Ustekinumab is a fully human immunoglobulin G1 kappa monoclonal antibody that binds the shared p40 subunit of interleukin (IL)-12 and IL-23. It is used to treat plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis. Ustekinumab was first authorized in the European Union on 16 January 2009. T...
Bimekizumab
go.drugbank.com/drugs/DB12917ApprovedInvestigational[A244455] It has demonstrated superior efficacy as compared to another IL-17 inhibitor, [secukinumab], as well as [ustekinumab] (an IL-12/23 inhibitor) and [adalimumab] (a TNF inhibitor) in the treatment